Spain's Iberdrola creates data centre joint venture with Ireland's Echelon
Iberdrola sees booming demand for data centres as one of the main drivers of future growth both for its grids and renewable energy businesses.
With developments like artificial intelligence and cloud computing expected to increase demand for data centre capacity, companies like Iberdrola can benefit both from selling them energy and connecting them to the grid.
The Spanish firm will have a 20% stake in the joint venture, providing energy and land connected to the grid.
Echelon will hold the remaining 80%, handling permitting, design, marketing and day-to-day management of data centres.
The joint venture already has a project in the pipeline: a 160,000 square meters complex with a data processing capacity of 144 megawatts. It has already secured a 230 MW electricity connection.
Expected to be operational by 2030, its 1 terawatt hour demand will be covered by a planned solar plant and additional green energy supplied by Iberdrola.
Iberdrola already supplies 11 TWh of energy to data centres in countries such as Spain, Britain, the U.S. and Germany. Last year, it created a data centre unit, CPD4Green, and had been seeking a partner.
"The alliance signed with Echelon will allow us to value our portfolio of sites with access to electricity connection and our ability to offer these infrastructures secure, clean and competitive energy 24 hours a day, 365 days a year," said David Mesonero Molina, corporate development director of Iberdrola.
With the deal, Echelon Data Centres - whose major shareholder is private investment firm Starwood Capital Group - achieves its strategic goal to enter the Spanish market, Chief Investment Officer David Smith said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth
British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 guidance. Driven by exceptional growth in Specialty Medicines and Vaccines, GSK's second-quarter sales reached $10.66 billion (7.98 billion British pounds), a 6% increase at constant currency, exceeding analyst estimates of $10.33 billion. Core earnings jumped 15% at constant currency to $1.24 per share (46.5 pence) outperforming the consensus forecast of $ company attributed this core earnings growth to the strong performance of its Specialty Medicines and Vaccines divisions, coupled with higher royalty income and a disciplined escalation of investment in key research and development (R&D) areas, particularly within Oncology and Vaccines. Vaccine sales jumped 5% (+9% at constant currency or cc) to 2.09 billion pounds, reflecting growth in Meningitis vaccines related to uptake following expanded recommendation and public funding of Bexsero in Europe, as well as growth in Shingrix driven by launch uptake in France and strong demand across several other European markets and Japan. Arexvy sales reached 66 million pounds, up 6% (+13% cc). Meningitis vaccine sales increased 17% (+22% cc) to 379 million, while established vaccine sales of 787 million increased 2% (+6% cc). Shingrix sales reached 853 million pounds, up 3% (+6% cc). In July, the FDA agreed to review the application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 who are at increased risk. Also in July, the FDA extended the review period for the Biologics License Application (BLA) for GSK's Blenrep combinations for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy. View more earnings on GSK Specialty Medicines sales grew by double-digit percentages (+10% and 15% cc) in the quarter to 3.33 billion pounds, reflecting continued growth across disease areas, with strong performances in HIV, Respiratory, Immunology & Inflammation, and Oncology. General Medicines sales fell by 10% (-6% cc) to 2.57 billion pounds. GSK is progressing on 14 major pipeline opportunities, each with a potential value of over 2 billion pounds, set to launch between 2025 and 2031. Phase 3 study for tebipenem, a new antibiotic for complicated urinary tract infections, was stopped early because it worked so well. The company plans to file for approval by the end of the year. Phase 3 development for depemokimab, aimed at treating COPD, has begun with the launch of the ENDURA study program. Key trials expected to begin in the second half of 2025 include GSK'227, a B7H3-targeting antibody-drug conjugate for small cell lung cancer, GSK'981 (IDRx-42) for second-line treatment of gastrointestinal stromal tumors, Efimosfermin for MASH, and an ultra-long-acting injectable HIV treatment combining cabotegravir and rilpivirine, to be given every four months. Tariff Outlook and Guidance Addressing a broader macroeconomic concern, GSK acknowledged the U.S. Administration's initiation of an investigation under Section 232 of the Trade Expansion Act, which seeks to ascertain the potential effects of pharmaceutical product imports on national security. The company said it is well-positioned to respond to the potential financial impact of tariffs, with mitigation options identified. According to Reuters, GSK's CFO indicated an anticipation of some tariffs coming in the second half of the year, which are expected to lower the gross margin slightly. GSK raised its full-year 2025 guidance and says it includes tariffs enacted thus far and the European tariffs indicated this week. It now expects sales to increase toward the top of the 3%–5% range. Core operating profit and earnings are also expected to grow towards the top end of the 6% to 8% range. Specialty Medicine sales are expected to increase in the low teens versus prior guidance of a low double-digit percentage. Vaccine revenue is expected to decline by a low single-digit percent to broadly stable compared to the prior outlook of a decrease of low single-digit percent, and general medicine sales are expected to be broadly stable. Price Action: At last check on Wednesday, GSK stock was up 3.57% to $40.37 during the premarket session. Read Next:Photo by HJBC via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? GSK (GSK): Free Stock Analysis Report This article GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Bayern Munich officially announces the signing of Luis Diaz.
Getty Images Although there was a lot of tug of war from Barcelona to acquire the player's services, it appears that the Spanish team has completely settled for signing Marcus Rashford, on loan from Manchester United, who will undoubtedly be the player who will occupy the left wing position. The deal for Nico Williams also fell through before the signing of Marcus Rashford, and now one of the Spanish club's targets, Colombian Luis Diaz, has officially become a Bayern Munich player on a four-year contract until 2029. How much did Bayern Munich pay for the Colombian? According to reliable press reports, most notably from Diario AS, Bayern Munich has spent the full amount of 70 million euros to acquire the services of the talented Colombian player from the English giants. Barcelona had submitted an official offer of no more than 60 million euros, which was rejected by Liverpool. Now, the Colombian will receive 17 million euros annually with Bayern Munich, which is three times his previous salary with Liverpool. "I'm very happy. It means a lot to me to be part of Bayern Munich – it's one of the biggest clubs in the world. I want to help my new team with my style of play and my personality. My goal is to win every possible title, and that's what we will work towards every day as a team" said the Colombian.
Yahoo
9 minutes ago
- Yahoo
HSBC's $300 Million Scandal Resurfaces -- Swiss Probe Reopens Risk for Global Bank
Swiss and French authorities have opened a new investigation into HSBC Holdings Plc's (NYSE:HSBC) Swiss private bank, reigniting concerns over legacy compliance risks that had long been buried. The probe centers on two historical client relationships, according to the bank's latest disclosure. While the details remain limited, HSBC warned investors that the potential impact on the firm could be materialthough the timing and outcome are still anyone's guess. Warning! GuruFocus has detected 6 Warning Sign with HSBC. This isn't the first time HSBC's Swiss arm has drawn regulatory heat. Just last year, Switzerland's financial regulator, Finma, found that the bank failed to perform adequate checks on politically exposed personsclients considered higher risk under anti-money laundering (AML) frameworks. Over $300 million in questionable transactions, processed between 2002 and 2015, were flagged. As a result, HSBC was ordered to tighten its AML controls and temporarily halt onboarding any new politically exposed clients. Now, with a fresh spotlight on its pastand scrutiny from two countriesHSBC's private banking business could be looking at a longer road to reputational repair. While this doesn't change the fundamentals overnight, it reopens old questions about governance and risk oversight. Investors watching from the sidelines may want to stay alert: depending on how the investigation unfolds, this story could evolve into a much bigger headline. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data